Oramorph (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Oramorph, is an opioid analgesic presented as an oral formulation for oral use. It treats moderate to severe pain in adult patients who require strong analgesia.

GNH USA supplies Oramorph as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oramorph, an opioid analgesic, is employed to manage pain conditions where strong relief is needed.

- Acute severe pain: provides rapid relief of intense postoperative or trauma‑related pain. - Chronic cancer pain: helps control persistent pain associated with malignant disease. - Severe neuropathic pain: reduces debilitating pain when other therapies are insufficient.

Morphine sulfate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset often occurring after dosing. - Constipation: reduced bowel motility leading to hard stools. - Drowsiness or sedation: mild to moderate sleepiness.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, or anaphylaxis in sensitive individuals.

When prescribing Oramorph, clinicians should consider several safety measures.

- Assess respiratory function: monitor for signs of breathing difficulty. - Monitor bowel habits: implement laxative regimen to prevent constipation. - Adjust dose in renal/hepatic impairment: reduce dosage as needed. - Avoid use in known hypersensitivity: discontinue if allergic reaction occurs. - Use only as directed: follow prescriber instructions closely. - Store at room temperature: keep in the original pack, protect from moisture.

Morphine sulfate can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension or serotonin syndrome. - CNS depressants (e.g., benzodiazepines): additive respiratory depression. - Respiratory depressants (e.g., barbiturates): heightened risk of fatal respiratory failure.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may increase morphine levels. - Antihistamines: can enhance sedation. - Diuretics: may exacerbate hypotension. - Anticholinergics: may worsen constipation.